The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
89bio Inc (ETNB)

89Bio operates as a clinical-stage biopharmaceutical company. Co. focuses on developing therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Co. serves customers in the United States and Israel.

Company Name:  89bio Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ETNB:  9
Total Market Value Held by ETFs:  $7.59M
Total Market Capitalization:  $421.00M
% of Market Cap. Held by ETFs:  1.80%
September 23, 2020    2:31 PM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Strong Buy (3.57 out of 4)
66th percentile
(ranked higher than approx. 66% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

89bio Inc (ETNB) Page | The Online Investor | | Copyright © 1998 - 2020, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.